October 2026 - Page 2 of 3 - Medical Genetics

A high percentile is not an absolute risk, and strong association does not establish that using a score improves care.

The same genetic condition can affect people differently. Penetrance and expressivity help explain what a genetic result can—and cannot—predict.

Small populations make endpoint selection more demanding, not less; connect measurement quality, natural history and patient relevance.

A one-time administration still requires long-term evidence about effectiveness, late adverse events and who remains represented in follow-up.

FAIR principles and responsible governance can support discovery while preserving consent, privacy and accountability.

Association identifies a genomic neighborhood; causal variants, target genes and biological effects require additional evidence.

A plausible variant cannot compensate for an uncertain relationship between the gene and the proposed disorder.

Conflicting classifications are a prompt to inspect evidence, scope and dates rather than count votes.

Reference databases are essential for variant interpretation, but absence, group labels and gene-level constraint each require careful qualification.

Finding a DNA change is only part of the question. Clinical actionability asks whether reliable evidence supports a useful response to that finding.